At AAIC2016, researchers from TauRx Therapeutics Ltd presented results from a phase III clinical trial of the drug leuco-methylthioninium-bis(hydromethanesulfonate) or LMTM in people with mild-to-moderate Alzheimer’s disease
Phase III tau drug fails to meet endpoints but shows silver lining as monotherapy
Leave a reply